Reuters logo
BRIEF-Caladrius Biosciences Inc says addition of four clinical sites for ongoing phase 2 study of CLBS03 in T1D
2017年4月3日 / 中午11点51分 / 6 个月前

BRIEF-Caladrius Biosciences Inc says addition of four clinical sites for ongoing phase 2 study of CLBS03 in T1D

April 3 (Reuters) - Caladrius Biosciences Inc

* Caladrius Biosciences Inc says addition of four clinical sites, including Joslin Diabetes Center, for ongoing phase 2 study of CLBS03 in T1D

* Caladrius Biosciences Inc says expects to reach important milestone of treating 50% of subjects by mid-2017

* Caladrius Biosciences Inc says enrollment of 70(th) subject in study, expected to occur in mid-2017, will trigger an additional infusion of capital Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below